Latest News

Vanguard S&P 500 ETF (TSX:VFV) is a go-to bet for many Canadians and for good reason.

Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company’s vice president and head of investor relations. Carlsen said

Loblaw combines defensive grocery and pharmacy demand with growing earnings, new stores, and a rising dividend.

Too busy to watch the market? These three set-and-forget stocks offer familiar businesses and dividends for a long-term Canadian portfolio.

The platform provider for the grocery industry reported a notable insider stock sale.

Zcash has been a standout performer this year, but its long-term track record is much less impressive.

Bruker (NASDAQ:BRKR) CFO Gerald Herman said the company’s second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing,

The insider maintains 462,980 shares worth $29 million after the sale, executed at prices just below market close during a period of strong stock performance.

The market, its dividend payers, and its largest growth stocks -- for about $3 a year in combined fees.

Oklo stock could easily triple if its project pipeline materializes.

Reddit just turned profitable with a new AI licensing revenue stream, while The Trade Desk commands steady growth and stronger cash generation, but their valuations tell opposite stories.

Archer's defense strategy could give it an edge over Joby.

Costco's shares have risen at an average annual rate of nearly 18% over the past 15 years. We can't assume that will continue -- but it might.

Waters (NYSE:WAT) President and Chief Executive Officer Udit Batra said the company’s second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses. Speaking at a JPMo

Both stocks deliver above-average yields, but one is definitely safer, and that one might surprise you.

And there could be more positive developments ahead.

AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enrolled 34 participants, with 25 receiving ACI-7104.056 and ni

The chipmaker already pledged up to $10 billion to the Claude maker last year. What would a second check buy?

Nike's fiscal Q1 results may not be enough to boost Nike stock.

As regular readers of my work across various websites are likely well aware, I have been expressing concerns that foreign interest in buying and owning U.S

Schwab U.S. Dividend Equity ETF is a solid high-yield option, but you may want to consider PepsiCo, Enterprise, and Realty Income instead.

The supply chain of loans could be in a crunch during an economic calamity.

The "force majeure" shows how complicated it has become to construct a data center on time.

That rule makes a lot of sense for this exchange-traded fund once you understand why it's in place.

BTCS (NASDAQ:BTCS) Chief Executive Officer Charles Allen outlined the company’s strategy to expand its decentralized finance operations, use on-chain borrowing to manage capital and emphasize gross profit as a key performance measure during a Water Tower Research Virtual Insights Conference. Allen